Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5G is an oral dietary supplement developed by Neurogenics Therapeutics, specifically formulated to support nerve health and address symptoms associated with peripheral neuropathy. The name 5G is derived from its five key active ingredients: methylcobalamin (Vitamin B12), benfotiamine (Vitamin B1), pyridoxal-5-phosphate (Vitamin B6), alpha-lipoic acid, and riboflavin (Vitamin B2). These components work synergistically to promote nerve regeneration, enhance myelin sheath integrity, and reduce oxidative stress. Methylcobalamin and benfotiamine provide highly bioavailable forms of essential vitamins that support nerve cell metabolism and structure, while alpha-lipoic acid acts as a potent antioxidant to mitigate nerve damage caused by free radicals. The product is marketed as a commercial solution for individuals seeking to manage neuropathic discomfort and maintain healthy neurological function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5G.